{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T19:52:43Z","timestamp":1770839563798,"version":"3.50.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2017,2,2]],"date-time":"2017-02-02T00:00:00Z","timestamp":1485993600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"an unrestricted grant from Research to Prevent Blindness (New York, NY)"},{"name":"a grant from the Knights Templar Eye Foundation"},{"name":"An Egyptian Government Joint Supervision Program Grant."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1007\/s11095-017-2110-x","type":"journal-article","created":{"date-parts":[[2017,2,2]],"date-time":"2017-02-02T16:48:33Z","timestamp":1486054113000},"page":"809-824","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Nimodipine Ophthalmic Formulations for Management of Glaucoma"],"prefix":"10.1007","volume":"34","author":[{"given":"Doaa Nabih","family":"Maria","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abd-Elgawad Helmy","family":"Abd-Elgawad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osama Abd-Elazeem","family":"Soliman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marwa Salah","family":"El-dahan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica M.","family":"Jablonski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,2,2]]},"reference":[{"issue":"3","key":"2110_CR1","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jcjo.2012.02.003","volume":"47","author":"C Cook","year":"2012","unstructured":"Cook C, Foster P. Epidemiology of glaucoma: what\u2019s new? Can J Ophthalmol. 2012;47(3):223\u20136.","journal-title":"Can J Ophthalmol"},{"issue":"9","key":"2110_CR2","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1111\/apt.12495","volume":"38","author":"EM Quigley","year":"2013","unstructured":"Quigley EM. Commentary: synbiotics and gut microbiota in older people--a microbial guide to healthy ageing. Aliment Pharmacol Ther. 2013;38(9):1141\u20132.","journal-title":"Aliment Pharmacol Ther"},{"issue":"10","key":"2110_CR3","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1001\/archopht.120.10.1268","volume":"120","author":"A Heijl","year":"2002","unstructured":"Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M. Early manifest glaucoma trial G. Reduction of intraocular pressure and glaucoma progression: results from the early manifest glaucoma trial. Arch Ophthalmol. 2002;120(10):1268\u201379.","journal-title":"Arch Ophthalmol"},{"issue":"2","key":"2110_CR4","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.ophtha.2008.08.051","volume":"116","author":"DC Musch","year":"2009","unstructured":"Musch DC, Gillespie BW, Lichter PR, Niziol LM, Janz NK, Investigators CS. Visual field progression in the collaborative initial glaucoma treatment study the impact of treatment and other baseline factors. Ophthalmology. 2009;116(2):200\u20137.","journal-title":"Ophthalmology"},{"key":"2110_CR5","doi-asserted-by":"crossref","unstructured":"Rodriguez-Aller M, Guinchard S, Guillarme D, Pupier M, Jeannerat D, Rivara-Minten E, Veuthey JL, Gurny R. New prostaglandin analog formulation for glaucoma treatment containing cyclodextrins for improved stability, solubility and ocular tolerance. Eur J Pharm Biopharm. 2015.","DOI":"10.1016\/j.ejpb.2015.04.032"},{"key":"2110_CR6","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.ejpb.2010.07.005","volume":"76","author":"P Jansook","year":"2010","unstructured":"Jansook P, Stef\u00e1nsson E, Thorsteinsd\u00f3ttir M, Sigurdsson BB, Kristj\u00e1nsd\u00f3ttir SS, Bas JF, et al. Cyclodextrin solubilization of carbonic anhydrase inhibitor drugs: formulation of dorzolamide eye drop microparticle suspension. Eur J Pharm Biopharm. 2010;76:208\u201314.","journal-title":"Eur J Pharm Biopharm"},{"key":"2110_CR7","first-page":"2201","volume":"9","author":"S Sharma","year":"2015","unstructured":"Sharma S, Trikha S, Perera SA, Aung T. Clinical effectiveness of brinzolamide 1%-brimonidine 0.2% fixed combination for primary open-angle glaucoma and ocular hypertension. Clin Ophthalmol. 2015;9:2201\u20137.","journal-title":"Clin Ophthalmol"},{"issue":"11","key":"2110_CR8","doi-asserted-by":"crossref","first-page":"2818","DOI":"10.1007\/s11095-013-1109-1","volume":"30","author":"MM Ibrahim","year":"2013","unstructured":"Ibrahim MM, Abd-Elgawad AH, Soliman OA, Jablonski MM. Novel topical ophthalmic formulations for management of glaucoma. Pharm Res-Dordr. 2013;30(11):2818\u201331.","journal-title":"Pharm Res-Dordr"},{"key":"2110_CR9","doi-asserted-by":"crossref","first-page":"7595","DOI":"10.1021\/nn301873v","volume":"6","author":"H Yang","year":"2012","unstructured":"Yang H, Tyagi P, Kadam RS, Holden CA, Kompella UB. Hybrid dendrimer hydrogel\/PLGA nanoparticle platform sustains drug delivery for one week and anti- glaucoma effects for four days following one-time topical administration. ACS Nano. 2012;6:7595\u2013606.","journal-title":"ACS Nano"},{"key":"2110_CR10","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ejphar.2013.10.073","volume":"739","author":"C Mayama","year":"2014","unstructured":"Mayama C. Calcium channels and their blockers in intraocular pressure and glaucoma. Eur J Pharmacol. 2014;739:96\u2013105.","journal-title":"Eur J Pharmacol"},{"key":"2110_CR11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijdevneu.2014.10.005","volume":"40","author":"K Sygnecka","year":"2015","unstructured":"Sygnecka K, Heine C, Scherf N, Fasold M, Binder H, Scheller C, et al. Nimodipine enhances neurite outgrowth in dopaminergic brain slice co-cultures. Int J Dev Neurosci. 2015;40:1\u201311.","journal-title":"Int J Dev Neurosci"},{"key":"2110_CR12","doi-asserted-by":"crossref","unstructured":"Rinkel GJ, Feigin VL, Algra A, van den Bergh WM, Vermeulen M, van Gijn J. Calcium antagonists for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev. 2005;CD000277(1):CD000277.","DOI":"10.1002\/14651858.CD000277.pub2"},{"issue":"2","key":"2110_CR13","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1080\/03639040500466270","volume":"32","author":"D Yang","year":"2006","unstructured":"Yang D, Zhu J, Zheng Y, Ge L, Zhang G. Preparation, characterization, and pharmacokinetics of sterically stabilized nimodipine-containing liposomes. Drug Dev Ind Pharm. 2006;32(2):219\u201327.","journal-title":"Drug Dev Ind Pharm"},{"key":"2110_CR14","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.colsurfb.2013.01.066","volume":"109","author":"Q Fu","year":"2013","unstructured":"Fu Q, Sun J, Zhang D, Li M, Wang YJ, Ling GX, et al. Nimodipine nanocrystals for oral bioavailability improvement: preparation, characterization and pharmacokinetic studies. Colloids Surf B: Biointerfaces. 2013;109:161\u20136.","journal-title":"Colloids Surf B: Biointerfaces"},{"key":"2110_CR15","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.colsurfb.2012.04.027","volume":"97","author":"SS Chalikwar","year":"2012","unstructured":"Chalikwar SS, Belgamwar VS, Talele VR, Surana SJ, Patil MU. Formulation and evaluation of nimodipine-loaded solid lipid nanoparticles delivered via lymphatic transport system. Colloids Surf B: Biointerfaces. 2012;97:109\u201316.","journal-title":"Colloids Surf B: Biointerfaces"},{"issue":"1","key":"2110_CR16","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ejpb.2012.12.016","volume":"84","author":"N Bege","year":"2013","unstructured":"Bege N, Renette T, Endres T, Beck-Broichsitter M, Hanggi D, Kissel T. In situ forming nimodipine depot system based on microparticles for the treatment of posthemorrhagic cerebral vasospasm. Eur J Pharm Biopharm. 2013;84(1):99\u2013105.","journal-title":"Eur J Pharm Biopharm"},{"issue":"1\u20132","key":"2110_CR17","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.ijpharm.2013.12.023","volume":"461","author":"X Liu","year":"2014","unstructured":"Liu X, Wang S, Chai L, Zhang D, Sun Y, Xu L, et al. A two-step strategy to design high bioavailable controlled-release nimodipine tablets: the push-pull osmotic pump in combination with the micronization\/solid dispersion techniques. Int J Pharm. 2014;461(1\u20132):529\u201339.","journal-title":"Int J Pharm"},{"key":"2110_CR18","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.ejps.2014.07.007","volume":"63","author":"SL Huang","year":"2014","unstructured":"Huang SL, Yu XH, Yang LL, Song FL, Chen G, Lv ZF, et al. The efficacy of nimodipine drug delivery using mPEG-PLA micelles and mPEG-PLA\/TPGS mixed micelles. Eur J Pharm Sci. 2014;63:187\u201398.","journal-title":"Eur J Pharm Sci"},{"key":"2110_CR19","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.neulet.2014.11.025","volume":"585","author":"LC Moreno","year":"2015","unstructured":"Moreno LC, Cavalcanti IM, Satyal P, Santos-Magalhaes NS, Rolim HM, Freitas RM. Acute toxicity and anticonvulsant activity of liposomes containing nimodipine on pilocarpine-induced seizures in mice. Neurosci Lett. 2015;585:38\u201342.","journal-title":"Neurosci Lett"},{"issue":"2","key":"2110_CR20","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1097\/00061198-200404000-00013","volume":"13","author":"F Michalk","year":"2004","unstructured":"Michalk F, Michelson G, Harazny J, Werner U, Daniel WG, Werner D. Single-dose nimodipine normalizes impaired retinal circulation in normal tension glaucoma. J Glaucoma. 2004;13(2):158\u201362.","journal-title":"J Glaucoma"},{"issue":"1","key":"2110_CR21","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1136\/bjo.2003.037671","volume":"89","author":"A Luksch","year":"2005","unstructured":"Luksch A, Rainer G, Koyuncu D, Ehrlich P, Maca T, Gschwandtner ME, et al. Effect of nimodipine on ocular blood flow and colour contrast sensitivity in patients with normal tension glaucoma. Br J Ophthalmol. 2005;89(1):21\u20135.","journal-title":"Br J Ophthalmol"},{"issue":"10","key":"2110_CR22","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1021\/js950534b","volume":"85","author":"T Loftsson","year":"1996","unstructured":"Loftsson T, Brewster ME. Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization. J Pharm Sci. 1996;85(10):1017\u201325.","journal-title":"J Pharm Sci"},{"issue":"1\u20132","key":"2110_CR23","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.ijpharm.2015.06.043","volume":"491","author":"F Najlaoui","year":"2015","unstructured":"Najlaoui F, Pigeon P, Abdelkafi Z, Leclerc S, Durand P, Ayeb ME, et al. Phthalimido-ferrocidiphenol cyclodextrin complexes: characterization and anticancer activity. Int J Pharm. 2015;491(1\u20132):323\u201334.","journal-title":"Int J Pharm"},{"key":"2110_CR24","first-page":"117","volume":"4","author":"T Higuchi","year":"1965","unstructured":"Higuchi T, Connors KA. Phase-solubility techniques. Adv Anal Chem Instrum. 1965;4:117\u2013212.","journal-title":"Adv Anal Chem Instrum"},{"issue":"3","key":"2110_CR25","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.ejpb.2006.11.013","volume":"66","author":"SW Jun","year":"2007","unstructured":"Jun SW, Kim M, Kim J, Park HJ, Lee S, Woo J, et al. Preparation and characterization of simvastatin\/hydroxypropyl-\u03b2-cyclodextrin inclusion complex using supercritical antisolvent (SAS) process. Eur J Pharm Biopharm. 2007;66(3):413\u201321.","journal-title":"Eur J Pharm Biopharm"},{"key":"2110_CR26","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ejps.2015.12.015","volume":"83","author":"C Mendes","year":"2016","unstructured":"Mendes C, Buttchevitz A, Kruger JH, Kratz JM, Simoes CM, de Oliveira BP, et al. Inclusion complexes of hydrochlorothiazide and beta-cyclodextrin: physicochemical characteristics, in vitro and in vivo studies. Eur J Pharm Sci. 2016;83:71\u20138.","journal-title":"Eur J Pharm Sci"},{"key":"2110_CR27","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.msec.2015.09.019","volume":"58","author":"S Desai","year":"2016","unstructured":"Desai S, Poddar A, Sawant K. Formulation of cyclodextrin inclusion complex-based orally disintegrating tablet of eslicarbazepine acetate for improved oral bioavailability. Mater Sci Eng C. 2016;58:826\u201334.","journal-title":"Mater Sci Eng C"},{"issue":"3","key":"2110_CR28","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1002\/jps.23417","volume":"102","author":"MM Ibrahim","year":"2013","unstructured":"Ibrahim MM, Abd-Elgawad AE, Soliman OA, Jablonski MM. Nanoparticle-based topical ophthalmic formulations for sustained celecoxib release. J Pharm Sci. 2013;102(3):1036\u201353.","journal-title":"J Pharm Sci"},{"issue":"3","key":"2110_CR29","doi-asserted-by":"crossref","first-page":"185","DOI":"10.2174\/156720107781023929","volume":"4","author":"AK Mehta","year":"2007","unstructured":"Mehta AK, Yadav KS, Sawant KK. Nimodipine loaded PLGA nanoparticles: formulation optimization using factorial design, characterization and in vitro evaluation. Curr Drug Deliv. 2007;4(3):185\u201393.","journal-title":"Curr Drug Deliv"},{"issue":"4","key":"2110_CR30","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1002\/jbm.a.30395","volume":"76A","author":"Y Zhang","year":"2006","unstructured":"Zhang Y, Zhuo R. Synthesis, characterization, and in vitro 5-fu release behavior of poly(2,2- dimethyltrimethylene carbonate)-poly(ethylene glycol)- poly(2,2-dimethyltrimethylene carbonate) nanoparticles. J Biomed Mater Res A. 2006;76A(4):674\u201380.","journal-title":"J Biomed Mater Res A"},{"issue":"3","key":"2110_CR31","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1208\/s12249-014-0257-x","volume":"16","author":"F Semcheddine","year":"2015","unstructured":"Semcheddine F, Guissi NE, Liu X, Wu Z, Wang B. Effects of the preparation method on the formation of true nimodipine SBE-\u03b2-CD\/HP-\u03b2-CD inclusion complexes and their dissolution rates enhancement. AAPS PharmSciTech. 2015;16(3):704\u201315.","journal-title":"AAPS PharmSciTech"},{"issue":"1\u20132","key":"2110_CR32","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.ijpharm.2015.07.075","volume":"493","author":"EB Basalious","year":"2015","unstructured":"Basalious EB, Shamma RN. Novel self-assembled nano-tubular mixed micelles of Pluronics P123, Pluronic F127 and phosphatidylcholine for oral delivery of nimodipine: In vitro characterization, ex vivo transport and in vivo pharmacokinetic studies. Int J Pharm. 2015;493(1\u20132):347\u201356.","journal-title":"Int J Pharm"},{"key":"2110_CR33","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.powtec.2015.03.029","volume":"278","author":"MK Riekes","year":"2015","unstructured":"Riekes MK, Caon T, Silva Jr J, Sordi R, Kuminek G, Bernardi LS, et al. Enhanced hypotensive effect of nimodipine solid dispersions produced by supercritical CO2 drying. Powder Technol. 2015;278:204\u201310.","journal-title":"Powder Technol"},{"key":"2110_CR34","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.ijpharm.2015.01.010","volume":"479","author":"SRS Rudrangi","year":"2015","unstructured":"Rudrangi SRS, Bhomia R, Trivedi V, Vine GJ, Mitchell JC, Alexander BD, et al. Influence of the preparation method on the physicochemical properties of indomethacin and methyl-b-cyclodextrin complexes. Int J Pharm. 2015;479:381\u201390.","journal-title":"Int J Pharm"},{"issue":"1","key":"2110_CR35","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1186\/1556-276X-6-260","volume":"6","author":"V Sanna","year":"2011","unstructured":"Sanna V, Roggio AM, Posadino AM, Cossu A, Marceddu S, Mariani A, et al. Novel docetaxel-loaded nanoparticles based on poly(lactide-co-caprolactone) and poly(lactide-co-glycolide-co-caprolactone) for prostate cancer treatment: formulation, characterization, and cytotoxicity studies. Nanoscale Res Lett. 2011;6(1):260.","journal-title":"Nanoscale Res Lett"},{"issue":"3","key":"2110_CR36","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1021\/acs.biomac.5b01526","volume":"17","author":"Z Zhang","year":"2016","unstructured":"Zhang Z, He Z, Liang R, Ma Y, Huang W, Jiang R, et al. Fabrication of a micellar supramolecular hydrogel for ocular drug delivery. Biomacromolecules. 2016;17(3):798\u2013807.","journal-title":"Biomacromolecules"},{"issue":"4","key":"2110_CR37","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/bip.20147","volume":"75","author":"R Banerjee","year":"2004","unstructured":"Banerjee R, Chakraborty H, Sarkar M. Host-guest complexation of oxicam NSAIDs with beta-cyclodextrin. Biopolymers. 2004;75(4):355\u201365.","journal-title":"Biopolymers"},{"issue":"1","key":"2110_CR38","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1177\/0192623307310945","volume":"36","author":"VJ Stella","year":"2008","unstructured":"Stella VJ, He Q. Cyclodextrins. Toxicol Pathol. 2008;36(1):30\u201342.","journal-title":"Toxicol Pathol"},{"key":"2110_CR39","doi-asserted-by":"crossref","unstructured":"Maria DN, Mishra SR, Wang L, Abd-Elgawad AH, Soliman OA, El-Dahan MS, Jablonski MM. Water-soluble Complex of Curcumin with Cyclodextrins: Enhanced Physical Properties For Ocular Drug Deliv. Curr Drug Deliv. 2016;13.","DOI":"10.2174\/1567201813666160808111209"}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-017-2110-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11095-017-2110-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-017-2110-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,25]],"date-time":"2017-06-25T09:37:26Z","timestamp":1498383446000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11095-017-2110-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,2]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["2110"],"URL":"https:\/\/doi.org\/10.1007\/s11095-017-2110-x","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"value":"0724-8741","type":"print"},{"value":"1573-904X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,2]]}}}